Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Free Report) have been assigned a consensus rating of “Hold” from the five research firms that are presently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $4.00.
A number of brokerages have recently issued reports on MCRB. The Goldman Sachs Group cut their price objective on shares of Seres Therapeutics from $1.00 to $0.75 and set a “sell” rating on the stock in a research report on Friday. StockNews.com raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, March 6th.
Read Our Latest Analysis on Seres Therapeutics
Institutional Trading of Seres Therapeutics
Seres Therapeutics Stock Up 8.1 %
Shares of Seres Therapeutics stock opened at $0.69 on Friday. The firm’s 50 day moving average price is $0.79 and its 200-day moving average price is $0.83. Seres Therapeutics has a 52-week low of $0.54 and a 52-week high of $1.53. The company has a market cap of $120.10 million, a P/E ratio of -3.00 and a beta of 2.19.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.
Read More
- Five stocks we like better than Seres Therapeutics
- The Basics of Support and Resistance
- How to Build the Ultimate Everything ETF Portfolio
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- The Significance of Brokerage Rankings in Stock Selection
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.